A research study on magic mushrooms in Canada highlighted that almost 80% of participants support the use of psilocybin as a medical treatment for distressed patients. Moreover, two-thirds of the Canadian participants in the same study believe that psilocybin should be legally accessible to those who require it.
Besides advocating for easier access to this substance, a significant 84.8 percent of participants suggest that the public health system should bear the costs of such treatments. A majority of Canadians view psilocybin as a feasible treatment option, especially for managing end-of-life distress.
[toc]
Key Findings:
- Residents of Québec, Ontario, Alberta, and British Columbia perceive psilocybin as a credible medicinal alternative for addressing end-of-life existential distress.
- Magic mushrooms are deemed safe for treating existential distress.
- Participants in two double-blind trials reported immediate and lasting benefits, with effects enduring for six months or more.
Understanding Existential Distress
Existential distress, akin to existential suffering, spiritual distress, and demoralization, arises when individuals confront their own mortality. This may lead to feelings of helplessness, isolation, anxiety, and a loss of purpose. This form of distress is particularly prevalent among patients with life-threatening illnesses, potentially resulting in a wish to hasten death or contemplation of suicide.
Generally, individuals diagnosed with terminal diseases or facing significant life changes are more likely to experience this form of distress. It can severely impact their mental health and overall quality of life.
Existential therapy aims to address issues like anxiety, depression, grief, loneliness, apathy, despair, identity confusion, and feelings of purposelessness and existential fear. However, it may require multiple sessions and may not be effective for everyone.
The questionable effectiveness of such therapy is a primary reason why many individuals seek alternative treatments.
Health Canada’s Stance on Psilocybin as a Therapeutic Option
In the last two decades, preliminary clinical studies have highlighted the potential advantages of psychedelic substances for treating complex mental disorders. Specifically, psilocybin has demonstrated its ability to provide rapid and sustainable relief from existential distress in patients approaching life’s end.
Recognizing the potential efficacy of these proposed psychedelic mushrooms, especially when conventional treatments fail, Health Canada revised the Special Access Program in 2022. This modification enables healthcare professionals to request controlled substances for their patients.
Canadian Advocacy for Psilocybin Access
An article presented in the Palliative Care Journal evaluates societal views on psilocybin-assisted therapy for end-of-life care. The study’s data comprises:
| Method | 2,800 Canadians from Québec, Ontario, Alberta, and British Columbia participated in the study. 19% of these participants had previous experience with psilocybin (15% in Québec, 26% in British Columbia). |
| Results | 79.3% view psilocybin-assisted therapy as a legitimate option for treating end-of-life existential distress. 63.3% believe psilocybin should be integrated into medical treatment. 84.8% advocate for this therapy to be provided by the public health system. 44.2% argue that healthcare professionals should administer the substance without the supervision of Health Canada. |
These findings align with surveys conducted in Canada, England, and Australia. The researchers stressed the uniqueness of their study, focusing on the use of psychoactive substances to alleviate existential distress in end-of-life situations.
Reasons for Canadian Endorsement of Psilocybin Use
An increasing number of Canadians support the utilization of psilocybin for therapy, primarily due to the evidence provided by esteemed research institutions. The perceived safety of psilocybin mushrooms for easing existential distress is another influential factor. Participants across several studies have not reported serious adverse health effects, such as multi-organ failure.
| Research | Procedure | Results |
| Johns Hopkins Study | 51 patients received a high dose of psilocybin and a low dose as an active placebo control | Immediate and prolonged The effectiveness of this therapy is primarily credited to mystical experiences which evoke a sense of unity and profound emotional revelations that provide benefits for up to six months or longer. |
| Trial at New York University | 29 patients were distributed randomly to either receive psilocybin or the active placebo, niacin. | The results were consistent with the Johns Hopkins study. Participants who were administered psilocybin reported a sense of psychological relief and a renewed outlook on life and death. |
| BMC Palliative Care | The study conducted interviews with nineteen participants, including 7 doctors, 4 working nurses, 4 chaplains, 3 social workers, and a psychologist. The study aimed to understand the perceptions of palliative care professionals on existential distress and their views on psychedelic therapy as a potential treatment. | Palliative care practitioners have expressed that psychedelic-assisted therapy (PAT) shows promise in alleviating existential distress. |
Patient Experiences
Empirical studies are not the only sources supporting the efficacy of psilocybin. Several accounts from patients highlight its potential to improve mental health and overall quality of life.
The Journey of Yokoi
Mio Yokoi, a terminal stage 4 pancreatic cancer patient, shares a transformative experience during her assisted therapy. She visualizes being on a raft, surrounded by nature and mythical creatures. This vision imbues her with a profound sense of the universe’s interconnectivity and support, providing her immense peace and confirmation.
In spite of receiving conventional mental health support, Yokoi continued to grapple with severe anxiety and distress following her diagnosis. Psilocybin therapy aided her in reestablishing a bond with her body and offered her a tangible feeling of love and support. This greatly improved her emotional and mental health.
The Story of Chrissy
Chrissy, a woman in her 50s, was diagnosed with stage 4 breast cancer that had metastasized to her lungs. At the time of the study, she worked full time as an administrative supervisor in healthcare and identified herself as an atheist. She was diagnosed with Generalized Anxiety Disorder during her screening.
Chrissy experienced significant reductions in anxiety, depression, fear of death, hopelessness, and demoralization. When asked about any shifts in her spiritual or religious beliefs following her therapy, she stated that her experiences had brought a sense of significance and authenticity to her beliefs.
Brenda’s Journey
Throughout her treatment, Brenda experienced the sensation of dying twice. However, she emerged from these episodes without fear of death, seeing it as a beautiful aspect of the cycle of life. She credited the study for initiating her healing journey from past trauma. The data gathered from her sessions reflect this profound change.
Notably, a decrease in anxiety and fear of death, as well as an increase in spirituality, were observed.
Available Psilocybin Mushroom Products in Canada
At present, access to psilocybin capsules and other products designed to address existential distress or other mental health issues may be limited. However, reliable online dispensaries remain a viable source for these products as needed.
| Characteristic | Brazilian Psilocybe Cubensis | Cambodian Psilocybe Cubensis | Melmac Psilocybe Cubensis |
| Origin | Native to Brazil and certain adjacent South American countries. | Discovered in Cambodia, particularly around the Angkor Wat Temple. | Linked to the Penis Envy mushrooms, which became popular in the 1970s. |
| Potency | Moderate potency; suitable for beginners. | Moderate potency as well; perfect for those new to the experience. | Highly potent; advised for individuals with intermediate to advanced experience. |
| Effects | Triggers a mental buzz, mild confusion, enhanced color perception, euphoria, spiritual experiences, increased creativity, and improved concentration. | Induces an invigorating and enduring high, slight visual changes, enhanced creativity, euphoria, a gentle physical high, fractal imagery, and feelings of joy. | Facilitates profound shamanic experiences, vision quests, intense mystical encounters, heightened creativity, concentration, social consciousness, and mood upliftment. |
Mitigate End-of-life Anxiety with Psilocybin Products
Existential or end-of-life distress can impose a hefty emotional burden on many patients nearing the end of their lives. Conventional treatments may not always be effective, leading to an increase in support across Canada for more accessible magic mushrooms within the public healthcare system. This growing public interest could We urge regulatory authorities to consider the potential of magic mushrooms as a viable treatment option. For all your psychedelic needs, including shroom delivery, consider Strongest Cubensis Strain Canada.
Frequently Asked Questions
What can patients expect from Psilocybin-Assisted Therapy?
The experiences of patients undergoing Psychedelic-Assisted Therapy (PAT) can differ significantly. It is crucial to prepare adequately and follow certain steps to ensure a positive outcome. Patients must undergo extensive screening and mental readiness exercises before consuming the substance.
- Preparation before the Session: Patients receive a thorough assessment. Therapists discuss the patient’s goals and expectations to set the session’s objectives. The therapist also explains the potential effects and what the patient can expect during the session.
- The Session: A controlled dose of the substance is administered to the patient in a comfortable, distraction-free environment that promotes relaxation and introspection. The therapist offers constant support and guidance throughout this process.
- Post-Session Integration Therapy: This therapy assists the patient in interpreting and processing their experiences. Further sessions provide ongoing support and counselling to reinforce the insights and transformations achieved during therapy.
How does psilocybin affect the brains of distressed patients?
Psilocybin interacts with the brain by binding to serotonin receptors, particularly the 5-HT2A receptor. This interaction can lead to changes in perception, mood, and cognition, resulting in considerable changes in consciousness, emotional breakthroughs, and new perspectives.
Is psilocybin therapy available to everyone?
Psilocybin therapy isn’t appropriate for everyone. Patients with specific mental health conditions or existential distress are rigorously screened, excluding those with a history of psychosis.
Related Articles:
